Next Phase Newsletter

A global private equity and venture capital firm with offices in the UK and the US has been investing in life sciences and healthcare for over 30 years and manages approximately $3.7 billion in AUM across several funds. The firm focuses on four key areas: therapeutics, dementia, healthcare growth, and medtech. For therapeutics, the firm is stage-agnostic and invests across all stages, from seed to crossover rounds approaching IPO. It also engages in company creation and building, allowing it to invest at very early stages in those cases. The average check size ranges from $5 million to $25 million, with the possibility of follow-on investments. While the firm prefers to lead, it is open to co-investing and will consider taking board positions on a case-by-case basis. As a transatlantic firm, the firm considers opportunities globally, with a focus on Europe and the US.

The firm invests in therapeutics, healthcare, and medtech. The therapeutics team is agnostic to both modalities and indications, considering a wide range of opportunities within the traditional therapeutics space. The firm is also stage-agnostic, investing at any stage from pre-clinical to late phases. In addition, the firm manages a separate fund which focuses exclusively on companies developing or enabling novel therapeutics for dementia.

The firm does not have specific requirements for the company or management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An early-stage investment fund supporting innovation across human health, food, agriculture, and climate is backed by sole LP, one of the world’s largest dairy exporters and producer of human nutrition products. The fund brings experience and expertise across both investing & operating in the Food and BioTech, ClimateTech and AgTech sectors. Its operating model allows access into the nearly 100 years of capability, ingenuity, manufacturing and distribution experience within its parent corporation, while maintaining the agility and responsiveness to be a strong partner to start-ups and innovators in the space.

The fund typically invests in seed to Series A opportunities, though remains open to companies at later stages. The average check size ranges from $2M to $5M USD, with the ability to go beyond this. The fund is open to both leading and co-investing and will consider board positions on a case-by-case basis. The fund is actively seeking opportunities globally and is open to deal structures beyond equity investments, such as co-development and in-licensing, especially for technologies that align strategically with it parent corporation.

The fund is generally interested in technologies that use nutrients to improve human health, such as those targeting the microbiome, cognitive function, sleep, and more. Areas of interest include the microbiome, alternative ingredients, and the application of molecules and proteins. The fund places a strong emphasis on data. In terms of development stages, the fund is open to working with companies from the pre-clinical stage through all phases of clinical and commercial development. The fund does not have specific requirements for the company or management team. However, the fund seeks founding teams with passion and strong technical expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Headquartered in London and New York with offices worldwide, a private equity firm managing ~$65M in assets under management (AUM). The firm invests in both public and private markets across various industries, with a healthcare-focused team dedicated to private market investments. Their average initial check size ranges from $10M to $30M, with follow-on investments expected. The firm has the ability to led, co-lead, or join a round as a syndicate member.

The firm is interested in opportunities in therapeutics, medical devices, and diagnostics. The firm is agnostic to subsectors and indications and is willing to consider orphan drugs. Within therapeutics, they prefer asset-forward companies but are open to platform companies with lead assets or drugs. Regarding the phase of development, the firm seeks clinical stage companies or companies that are no more than 6-9 months away from the clinical stage.

The firm doesn’t have specific requirements for companies’ management teams. The firm will consider board or observer seats on a case-by-case basis, but this is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A boutique venture capital firm headquartered in Boston with a global outreach and epicenter in Dubai has invested alongside Tier 1 VCs in 12 companies with 5 exits qualified as unicorns. The firm is stage-agnostic and can invest at any stage. With this said, check sizes are flexible and can range from $500K – $15M. Their capital comes mostly from qualified purchasers (investors) located in the MENA region at large and GCC region specifically. To date, the firm has invested in USA based companies.

The firm is focused on healthcare, energy, ICT and infotech and most recently data defined networks addressing the systems aging and longevity (and research at large) pain points. The firm has invested in medi-tech, health-tech and biotech in the past which includes but not limited to diagnostics, medical devices, therapeutics, and digital health. The firm invests within 4 pillars of longevity roadmap covering health span and lifespan namely: (a) preventative, (b) replacement, (c) biostasis, and (d) therapeutics and genetic engineering on the basis that they are targeting systems aging and longevity. The firm prefers a management team with domain expertise, past performance and PhD’s / higher educational pedigree.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital and private equity firm making investments in life sciences will invest as early as Series A and through growth transactions. The firm looks to invest between $10 million and $40 million per investment. The firm has a preference for funding companies with a de-risked clinical development pathway, often via established mechanisms of action, repurposed/reformulated programs, 505(b)(2)s, and/or proof of concept clinical efficacy data. 
 
The firm has a primary focus on pharmaceuticals / therapeutics, and a secondary focus on medical devices. The firm is agnostic to indication. 
 
The firm plays an active role in their portfolio companies. The firm will take a board seat with any company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with ties to a family office invests mainly in Seed to Series A/B, with an initial check ranging between 3-7 million Euros. Follow-on investments are possible, and the firm may invest up to 15 million Euros throughout the life cycle. The firm is open to both leading and co-investing. The firm focuses on opportunities in Europe, UK and US. 
 
The firm is interested in early-stage therapeutic technologies. The firm is agnostic regarding modalities and indications, and is open to exploring different types of therapeutic assets. Additionally, the firm has invested in orphan drugs. While there is no strict mandate for the development phases of assets, having at least in-vivo data would generally be preferred. 
 
There are no specific requirements for companies’ management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2019 and headquartered in Europe invests in healthtech startups in Pre-Seed to Seed stages across Europe as well as in the U.S., Canada, Israel, and Australia. Typical check size ranges from €200k-1.5M EUR, and the firm can lead rounds, co-invest, or follow. 
 
The firm invests in healthcare companies that involves data information, technology, hardware, software, AI, and medtech that includes a strong data or computing component. The firm will not look at traditional medical devices such as surgical devices that does not have data components or traditional biotech such as therapeutics and drug development. The firm has broad indications and will look at different needs across the entire healthcare system such as need-based solutions for providers, better operations on the backend, direct solutions for patients, clinical trial needs, payer and insurance company solutions, and medical education platforms. 
 
The firm often takes a board or observer seat though not required. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.